Supercomputing and drug discovery research

A primary role of computational science and supercomputing technology in pharmaceutical research is to expedite the discovery and development process using a balance of database applications, data generation applications, and data analysis and visualization applications. Data generation applications include familiar algorithms based on physical theory, such as molecular mechanics and quantum mechanics. The usefulness of computational chemistry to the pharmaceutical (and chemical) industry depends on its ability to provide knowledge about the structure and properties of substances and the transformations they undergo. The complexity of realistic model calculations and the time-critical nature of the results require high-performance computing to discover and test ideas for novel compounds that will be useful in therapeutic intervention.

[1]  J. Howbert,et al.  Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas. , 1992, Chemical research in toxicology.

[2]  F E Cohen,et al.  Structure-based inhibitor design by using protein models for the development of antiparasitic agents. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Rainer Franke,et al.  Theoretical drug design methods , 1984 .

[4]  R. M. Justice,et al.  The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. , 1990, Biochemical and biophysical research communications.

[5]  Charles David Jones,et al.  QSAR study of benzoquinolinones as inhibitors of human type 1 5-α-reductase. , 1993 .

[6]  M. W. Daniels,et al.  AN ALPHANUMERIC AND GRAPHIC LIMS FOR ROUTINE PHYSICAL CHEMISTRYB ANALYSES , 1992 .

[7]  Donald B. Boyd,et al.  Application of the hypersurface iterative projection method to bicyclic pyrazolidinone antibacterial agents. , 1993, Journal of medicinal chemistry.

[8]  D B Boyd,et al.  Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones. , 1991, Journal of medicinal chemistry.

[9]  D K Herron,et al.  Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists. , 1992, Journal of medicinal chemistry.

[10]  Donald B. Boyd,et al.  Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones. , 1991, Journal of medicinal chemistry.

[11]  Jack B. Deeter,et al.  3-exo-methylenecephalosporins : structure and thermodynamics by experiment and theory , 1991 .

[12]  T. Lindstrom,et al.  Benzylamine antioxidants: relationship between structure, peroxyl radical scavenging, lipid peroxidation inhibition, and cytoprotection. , 1993, Journal of medicinal chemistry.

[13]  J. S. Sawyer,et al.  Optimization of the quinoline and substituted benzyl moieties of a series of phenyltetrazole leukotriene D4 receptor antagonists. , 1992, Journal of medicinal chemistry.

[14]  John M. McGill,et al.  Structural and conformational analysis of (E)‐erythromycin A oxime , 1993 .

[15]  Donald B. Boyd,et al.  Synthesis and in Vitro Evaluation of N‐[[4‐[2‐(Carboxyl)‐1‐Cycloalken‐1‐yl]Phenyl]Methyl]Imidazoles as Nonpeptide Angiotensin II Receptor Antagonists , 1993 .

[16]  J. Drazen,et al.  Leukotriene receptor on U-937 cells: discriminatory responses to leukotrienes C4 and D4. , 1991, The American journal of physiology.

[17]  Donald B. Boyd,et al.  Molecular simulations of DD‐peptidase, a model ß‐lactam‐binding protein: Synergy between X‐ray crystallography and computational chemistry , 1991 .

[18]  Edward Borowski,et al.  Molecular Aspects of Chemotherapy , 1990, Springer Berlin Heidelberg.

[19]  D B Boyd,et al.  Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity. , 1992, Journal of medicinal chemistry.

[20]  D. Clawson,et al.  Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 Å resolution , 1991, Nature.

[21]  Robert B. Hermann,et al.  OVID and SUPER: Two overlap programs for drug design , 1991, J. Comput. Aided Mol. Des..

[22]  Donald B. Boyd,et al.  Insight into Lactam Antibiotics and their Receptors from Computational Chemistry , 1992 .

[23]  M O Chaney,et al.  Characterization of the spatial arrangement of the two acid-binding sites on the human neutrophil LTB4 receptor. , 1992, Receptor.

[24]  J Ellis,et al.  Structure/function relationships of muscarinic acetylcholine receptors. , 1993, Life sciences.

[25]  James H. Wikel,et al.  The use of neural networks for variable selection in QSAR , 1993 .

[26]  Paul L. Dubin,et al.  Electrophoretic and Quasi-Elastic Light Scattering of Soluble Protein-Polyelectrolyte Complexes , 1993 .

[27]  D. Lodge,et al.  3-Phenyl-4-hydroxyquinolin-2(1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex. , 1992, Journal of medicinal chemistry.

[28]  D. D. Wirth,et al.  Carboxylic sulfonic mixed anhydrides: General utility and application to the synthesis of ceftazidime , 1993 .

[29]  Robert B. Hermann,et al.  Calculation of hydrophobic interactions from molecular dynamics, surface areas, and experimental hydrocarbon solubilities , 1993, J. Comput. Chem..

[30]  K Y Hui,et al.  Model peptides to study the effects of P2 and P3 substitutions in statine‐containing HIV proteinase inhibitors , 1993, FEBS letters.

[31]  Larry Smarr,et al.  Supercomputing and the transformation of science , 1993 .

[32]  J S Ward,et al.  Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore. , 1992, Journal of medicinal chemistry.

[33]  Gordon L. Nelson,et al.  Fire and polymers : hazards identification and prevention : developed from a symposium sponsored by the Macromolecular Secretariat at the 197th National Meeting of the American Chemical Society, Dallas, Texas, April 9-14, 1989 , 1990 .

[34]  R. F. Brown,et al.  Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins. , 1990, Journal of medicinal chemistry.

[35]  Melvin J. Yu,et al.  Enzymic and nonenzymic lipid peroxidation: inhibition by substituted phenoxazines , 1991 .

[36]  Ralph E. Christoffersen,et al.  Computer-assisted drug design , 1979 .

[37]  Donald B. Boyd,et al.  Molecular modeling of γ-lactam analogues of β-lactam antibacterial agents: synthesis and biological evaluation of selected penem and carbapenem analoques , 1989 .

[38]  Norris Parker Smith,et al.  The supercomputer era , 1987 .

[39]  R. W. Harper,et al.  Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships. , 1990, Journal of medicinal chemistry.

[40]  Holger Wallmeier,et al.  Computer‐Assisted Molecular Design (CAMD)—An Overview , 1987 .

[41]  Dale E. Mais,et al.  Thromboxane A2 receptor antagonists. Synthesis and activities of phenylsulfonamido derivatives , 1991 .

[42]  J. Deeter,et al.  Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin receptor ligands. , 1992, Journal of medicinal chemistry.

[43]  Samuel J. Strada,et al.  The biology of cyclic nucleotide phosphodiesterases. , 1992, Advances in second messenger and phosphoprotein research.